Mucosis intends to bring its candidate vaccines into early phase clinical development leveraging non-dilutive funding where available. For later stage clinical development and marketing of our vaccines, we intend to further increase the value of our programs and products by collaborating with both international and local partners that have established a strong regulatory and business presence in the vaccine industry.
Products with first mover and/or competitive advantages.
We have selected lead vaccine candidates that either target disease areas which have a substantial unmet medical need either in new disease areas or outperform the currently available vaccines by means of patient friendliness and efficacy, such as SynGEM® and PneuGEM® respectively. Our human proof-of-concept product FluGEM® is an intranasal influenza vaccine which established the viability of the platform to safely and effectively deliver antigens intranasally.
Leveraging the value of our technology by licensing.
We have developed a plug & play vaccine technology that can be used to develop a portfolio of vaccine products. Therefore, we will license our technology to third parties for use in their in-house vaccine development programs. This will generate short term licensing revenue and future revenue from royalty on sales of the products that are developed with our technology. These revenues will be used to accelerate the development of Mucosis’s own in-house vaccine programs.